ATAI Life Sciences NV held its annual general meeting of shareholders on May 15, 2025. The shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year 2024. Deloitte & Touche LLP and Deloitte Accountants B.V. were appointed as the external auditor for fiscal year 2025. Members of the supervisory and management boards were released from liability for the exercise of their duties during fiscal year 2024. The authorization of the management board to issue shares and grant rights to subscribe for shares was extended. The management board's authorization to limit and exclude pre-emption rights was also extended. Additionally, the authorization of the management board to acquire shares or depositary receipts for such shares in the company's capital was extended.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。